Here at Deals of the Week, we don’t often take note explicitly of buyouts outside the biopharma sphere. But one well-publicized tech deal ...

While the largest deal of the week, and certainly the one receiving the most attention, has been Actavis' expansion of its branded p...

The last few years have been quite a bash for biotech. Astoundingly, the NASDAQ Biotechnology Index (NBI) has added more now than it did du...

In tandem with a 10-company effort launched in September to resolve clinical development hurdles, three pharmas are coming together to e...

It’s always interesting to hear Mike Pearson, the blunt CEO of Valeant, expound on how nimbly his company is responding to Pharma’s co...

Late spring has meant another foray by activist investor Carl Icahn into the forest of biotech board manipulation - literally this time, ...

It's that time of year. The science of bracketology has yet to enliven talk around the water cooler, the official start to the 2011 ba...